Kester doubles money on Chiltern sale
Kester Capital has sold its stake in clinical services business Chiltern, reaping a 2x money multiple and a 25% IRR.
Kester sold its stake to existing investors, led by businessman Sir Douglas Myers and including management.
Kester, then Greenhill Capital Partners Europe, invested an undisclosed amount in the first round of funding for Chiltern via its GCPE Fund. The stake was acquired from one of the investors who backed a previous MBI in 2006.
Company
Founded in 1982, Chiltern is a clinical contract research organisation (CRO) that notably manages phase I-IV clinical trials across a range of therapeutic areas, and also provides functional service provision and contract staffing solutions. The business offers services in early-phase, global clinical development, late-phase, biometrics, medical and regulatory affairs as well as resourcing solutions.
Bath-based Chiltern employs more than 1,600 people globally and posted a £104m turnover in the year ending in March 2013 - up 17% on the previous year.
People
Adam Maidment led the deal for Kester Capital.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds








